Form 4: Progyny EVP Sells Shares Under 10b5-1 Plan
Insider Transaction Report
Progyny's EVP and General Counsel, Allison Swartz, sold 599 shares of common stock on March 4, 2026, under a pre-arranged 10b5-1 trading plan.
Summary
- Allison Swartz, Executive Vice President and General Counsel of Progyny, Inc. (PGNY), reported transactions on March 4, 2026.
- 339 shares of common stock were withheld for tax payments upon the vesting of restricted stock units at a price of $17.52 per share.
- An additional 599 shares of common stock were sold at $17.54 per share.
- The sale of 599 shares was executed pursuant to a Rule 10b5-1 trading plan established on May 13, 2025.
- Following these transactions, Allison Swartz beneficially owns 88,941 shares of Progyny common stock.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event. The sale is a routine transaction under a pre-arranged 10b5-1 plan, which typically does not signal a change in management's confidence in the company.
Future Outlook
NA
Industry Context
StockSavvy.ai notes that routine insider sales, especially those executed under pre-arranged 10b5-1 plans, are common practice for executives to manage personal finances and diversify holdings without implying a negative outlook on the company. This is typical for executives in the healthcare benefits or fertility services industry.
Stakeholder Impact
- Minimal direct impact on shareholders as this is a routine, pre-scheduled executive stock sale and tax withholding, not indicative of a shift in company fundamentals or strategy.
Key Dates
| Date | Description |
|---|---|
| May 13, 2025 | Date Rule 10b5-1 trading plan was entered into. |
| March 4, 2026 | Date of reported transactions (shares withheld for taxes and shares sold). |
| March 6, 2026 | Date Form 4 was signed by Attorney-in-Fact. |
Recommendation
holdThe filing details a routine insider stock sale executed under a pre-arranged 10b5-1 plan. Such transactions are common for executive compensation and personal financial management and typically do not reflect a change in the company's fundamental outlook or warrant a change in investment recommendation based solely on this disclosure. Therefore, a 'hold' recommendation is appropriate as this event is neutral.
Keywords
Progyny, PGNY, Allison Swartz, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, Restricted Stock Units, Executive Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.